Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

Losartan metabolite EXP-3174 does not possess antiarrhythmic properties

May 31, 2000

Azimilide and dofetilide highlighted at NASPE

May 31, 2000

Microbially produced NO inhibitor presented by Pola

May 30, 2000

EGF-genistein prevents restenosis in vivo

May 30, 2000

Alexion reports on complement activation in cardiovascular disease and kidney damage

May 30, 2000

Age and gender found to have significant effects on cardiovascular disease treatment outcomes

May 30, 2000

Advantages of Specific RAAS Blockage -- Internet Webcast available to Daily Essentials readers

May 29, 2000

BMS and Ligand establish cardiovascular collaboration

May 26, 2000

Endovasc given green light to proceed to clinical trials with Liprostin

May 26, 2000

Compounds blocking ICAM-1 activity described by Roche

May 25, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....